Skip To Main Content

Search

For optimal search results, please limit to 2 product keywords

If you are searching for information related to a product:

  • For optimal results, please enter at least 2 search terms in addition to product name
  • Example: [product name] [search term] [search term]
  • Example: Product + clinical trials
  • For an exact match, please include search terms in double quotations. For example: "health equity"

Susvimo (ranibizumab injection) for intravitreal use via SUSVIMO ocular implant

Video conference chat

Surgical Education

Susvimo® Surgical Education Publications and Congresses

Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab

Awh CC, Barteselli G, Makadia S, et al. Management of Key PDS Ocular Adverse Events. Ophthalmology 2022;129(12):1336-1341

Conjunctiva and Tenon’s Capsule Handling in the Port Delivery System with Ranibizumab Implant Insertion Procedure: Surgical Pearls

Graff JM, Sheth VS, Chang RT, et al. Conjunctiva and Tenon’s Capsule Handling in the Port Delivery System with Ranibizumab Implant Insertion Procedure: Surgical Pearls. Ophthalmic Surg Lasers Imaging Retina. 2022;53:266-273.

Refill-Exchange Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Trial Experience

Khanani AM, Graff JM, Marcus DM, et al. Refill-Exchange Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Trial Experience. Ophthalmic Surg Lasers Imaging Retina. 2022;53:257-265.

Implant Insertion Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Pearls

Pieramici DJ, Wieland MR, Stewart JM, et al. Implant Insertion Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Pearls. Ophthalmic Surg Lasers Imaging Retina. 2022;53:249-256.

Exudation in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery System or Monthly Injections

Akhlaq A, Williams D, Clark WL, et al. Exudation in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery System or Monthly Injections. American Journal of Ophthalmology. 2024; 258: 158-172.

Endophthalmitis in Eyes Treated With the Port Delivery System With Ranibizumab: Summary of Cases During Clinical Trial Development

Eichenbaum DA, Freeman WR, Chang MA, et al. Endophthalmitis in Eyes Treated With the Port Delivery System With Ranibizumab: Summary of Cases During Clinical Trial Development. Ophthalmology Retina. 2024; In Press, Corrected Proof, Available online 16 August 2024.

Technical Updates to Port Delivery System With Ranibizumab (PDS) and Clinical Experience With Updated Refill Needle

Pieramici D, Pearce I, Campochiaro P, et al. Technical Updates to Port Delivery System With Ranibizumab (PDS) and Clinical Experience With Updated Refill Needle. Presented at the 42nd Annual Scientific Meeting of the Americal Society of Retinal Specialists at Stockholm, Sweden on July 18, 2024.

Looking for more information?

Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT

The information in this section may include content beyond what is in the FDA-approved label. Because the FDA has not approved such content, no conclusions regarding safety or efficacy may be made. Providing this information should not be construed as recommendation for use of a Genentech product for unapproved uses. For FDA-approved products please consult the product’s full prescribing information for a complete discussion of risks and benefits of the product(s) for its approved indication(s).

To view a PDF of the above document, please click here.

A Genentech Medical Science Liaison in your area can assist with medical questions about Susvimo® and other Genentech products.

Publications icon

Publications and Congresses

The information in this section may include content beyond what is in the FDA-approved label. Because the FDA has not approved such content, no conclusions regarding safety or efficacy may be made. Providing this information should not be construed as recommendation for use of a Genentech product for unapproved uses. For FDA-approved products please consult the product’s full prescribing information for a complete discussion of risks and benefits of the product(s) for its approved indication(s).

Publications: The list of publications is not an exhaustive list of published materials on the product. The list of references by data topics is selected per evidence-based medicine criteria. To browse a full listing of published scientific literature:

Congresses: The list of congresses is a subset of Roche/Genentech posters and oral presentations for the product with data presented at scientific meetings in the recent 24 months. To browse full Roche/Genentech congress presentations and posters:


Filters

Susvimo® (ranibizumab injection) for intravitreal use via Susvimo

Showing 39 out of 39 results

No results

Try resetting the filters or selecting another category.

Looking for more information?

Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT